

Ohio Psychiatric Physicians Association
2023 Annual Psychiatric Update

***Putting the Unique Needs
of our Patients First:
Compassion, Controversies &
Crucial Conversations***



April 22-23, 2023
Marriott University
Columbus, OH

This is an in-person educational event

Jointly provided by American Psychiatric Association and
Ohio Psychiatric Physicians Association



General Information

REGISTRATION

The preferred method of registration is online at www.ohiopsychiatry.org/annualpsychupdate. If you register by mail, please complete the registration form on page 11 and send with payment to: Ohio Psychiatric Physicians Association, PO Box 400, Dublin, OH 43017. Make check payable to OPPA. Your registration is not confirmed until payment is received. Non-member psychiatrists who join OPPA/APA by April 30, will receive \$150 applied to OPPA dues (please select this option on the registration form and a representative from OPPA will contact you with further details.)

HOTEL ACCOMMODATIONS

A limited number of rooms have been set aside until **April 8** at the rate of \$160 single/double, plus applicable tax at the Marriott Columbus University Area, 3100 Olentangy River Rd., Columbus, OH 43202. To reserve a room please contact the hotel ASAP at 1-800-MARRIOTT and ask for the OPPA's room block or go to <https://www.marriott.com/event-reservations/reservation-link.mi?id=1674058034604&key=GRP&app=resvlink>.

AMERICANS WITH DISABILITIES ACT

If you need assistance related to sight, sound, or mobility, please contact the OPPA office as soon as possible so that we may accommodate reasonable requests.

SYLLABUS

Every registered attendee will receive a printed syllabus at registration.

MEALS

A breakfast and lunch buffet will be provided on Sat., April 22 and a continental breakfast will be provided on Sun., April 23.

CANCELLATION POLICY

If you are not able to attend, we encourage you to send someone in your place. Refund of the registration fee, minus a \$50 administrative charge will be allowed if request for cancellation is received in writing by Mar. 23, 2023. After this date no refund will be made.

SPONSOR A MEDICAL STUDENT

In an effort to give medical students more opportunities to experience psychiatry, including being mentored by a practicing psychiatrist, and receive cutting-edge psychiatric education, the Ohio Psychiatric Physicians Foundation (OPPF) encourages meeting attendees to "sponsor" a medical student by paying the registration fee for a medical student to attend the OPPA Annual Psychiatric Update. This is just one of the ways the OPF is working to encourage students to consider psychiatry as their specialty.

Your support can be accomplished in one of two ways:

- 1) If you have a specific student whom you wish to sponsor, simply complete the registration form, making sure to include the student's contact information; or
- 2) If you do not have a particular student in mind, we will pair you up with a medical student who has indicated an interest in attending if there is a sponsorship available – simply complete the registration form, leaving that information blank and you will be contacted by the OPPA office closer to the time of the actual meeting. If you are unable to attend the meeting, you may still sponsor a student by making a tax-deductible contribution to the OPF for this purpose.

In order to make this a tax-deductible contribution, the registration and the sponsorship must be processed in two separate transactions. If paying by check, please mail two checks. Please make the sponsorship check payable to Ohio Psychiatric Physicians Foundation (OPPF) and your event registration check payable to OPPA.

MEDICAL STUDENTS

Students may apply for a sponsorship by completing the [Medical Student Sponsorship Request form](#). Students will be notified by April 12, 2023 if there is a sponsorship available. Priority will be given to students who have not attended in the past. There will be time at a designated student breakfast to meet with other Ohio medical students and to learn from residents and others about psychiatry residency and career opportunities.

CME CERTIFICATE

Instructions with an access code for obtaining your CME certificate online, directly from the APA, will be provided during the conference. You will complete an evaluation form online. Once you complete the evaluation and attest to the number of hours of credit you are claiming for this educational event, a certificate will be available for immediate download/printing.

Poster Presentations

CALL FOR ABSTRACTS

The Ohio Psychiatric Physicians Association (OPPA) and Ohio Psychiatric Physicians Foundation (OPPF) invite all OPPA members, resident/fellows and medical students to participate by submitting an abstract for consideration to display a poster presentation during the upcoming Annual Psychiatric Update to be held on April 22-23, 2023. If the abstract is accepted, the presenting author(s) will be expected to register and attend the meeting to showcase and discuss the poster with the judges on-site.

SUBMISSION GUIDELINES

- Members and residents/fellows must be an OPPA member. Medical students must be members of the American Psychiatric Association.
- Submission areas may include research reports, research-in-progress, case reports, and posters that have already been presented elsewhere within the past year.
- **All abstracts must be received by 11:59 pm on March 7, 2023 for consideration for inclusion in the 2023 posters.**

INFORMATION REQUIRED FOR SUBMISSION OF ABSTRACT

- Title
- Name of author(s)
- Name of presenter(s)
- Information of author(s) (contact information, level of training or years in practice, degrees, title, institution name, address, phone number, and email address).
- Abstract (500 words or less).
- The disclosure form (see below) is due at the time of abstract submission.
- All submission materials must be completed online. Click [HERE](#) to access the submission form or go to www.oppa.org/foundation, under Awards section
- Incomplete submissions will not be considered.

POSTERS

Typically, virtual posters have two aspects, a PDF poster, and a short description:

- Posters — Poster display boards will be 48 inches wide and 36 inches high; pins/clips will be provided.
- Presenting author(s) are required to personally attend their poster for the duration of the assigned judging times. Specific details will be provided prior to the event.
- Posters will be required to be on-site for the duration of the conference, and any posters remaining after the conclusion of the conference will be discarded.
- PDF Descriptions — Presenters should provide a PDF, along with a written description of the poster.
- **If abstract is selected, posters (PDF and description) is due by April 15, 2023**

THE REVIEW PROCESS

- Judges will be appointed by the OPPF Board to the Poster Awards Committee.
- Abstract submissions will be reviewed for acceptance by the OPPF Poster Awards Committee.
- Selection criteria include educational value, audience appropriateness and topic diversity.
- Specific details about the judging process will be provided when the abstract is accepted.

GENERAL DISCLOSURE POLICY

- Every presenter must complete a [Disclosure of Financial Interests form](#) through the OPPA's online submission site.
- Each presenter must make every effort to ensure meaningful disclosure of limitations on data (e.g. ongoing research, interim analysis, preliminary data, or unsupported opinion).

Overview

OVERALL LEARNING OBJECTIVES

At the conclusion of this educational event, participants should be able to:

Sat., April 22

- ◆ Examine the social context of health care in the U.S. and globally.
- ◆ Explain health equity and its relationship to the social determinants of health and health disparities.
- ◆ Explore a gaze into the future of health care and sustainability for all.
- ◆ Incorporate the possibility of pregnancy into the psychiatric treatment of reproductive age women.
- ◆ Critically appraise the research on pregnancy termination and mental health.
- ◆ Understand the potential implications of *Dobbs v. Jackson* on the field of psychiatry.
- ◆ Describe the pharmacokinetic and pharmacodynamic changes associated with aging.
- ◆ Discuss the benefits and risk of using psychopharmacological agents in older adults.
- ◆ Enumerate evidence-based guidelines for the treatment of some common psychiatric disorders among older adults.
- ◆ Describe three unintended negative consequences from the “chemical imbalance” explanation of depression.
- ◆ State how symptoms of depression can be explained in ways that don’t invoke neurochemical aberration.
- ◆ Describe what antidepressant medications do, aside from augmenting monoamine signaling.
- ◆ Describe the prevalence of different forms of trauma experienced by children and adolescents.
- ◆ Differentiate PTSD from other diagnostic conceptualizations for children and adolescents experiencing complex trauma.
- ◆ Explain the core components of evidence-based psychotherapeutic treatments for trauma-exposed children and adolescents.

Sun., April 23

- ◆ Explain harm reduction as a framework and provide different examples of harm reduction tools and practices.
- ◆ Understand the health impact on people who use drugs of inequitable drug policies and stigma.
- ◆ Consider non-judgmental, person-centered, harm reduction practices to foster better systems of support and trust in our places of work and communities.
- ◆ Explain the content for behavioral health inequities for transgender and gender diverse (TGD) people, across diagnostic categories within a gender minority stress framework.
- ◆ Describe culturally responsive tailoring of evidence-based clinical practices for TGD people.
- ◆ Apply strategies for building inclusive, affirming, and trauma-informed environments within mental health care settings to optimize outcomes for TGD people.
- ◆ Recognize the new antidepressant drugs with novel mechanisms of action beyond the monoamines.
- ◆ Describe the newly developed antipsychotic medications with novel, non-dopaminergic mechanisms of action.
- ◆ State the two major unmet needs of negative and cognitive symptoms of schizophrenia and the experimental drugs being tested for their treatment.

WHO SHOULD ATTEND

This program is designed specifically for Psychiatrists, Residents, Medical Students and other Physicians, including Primary Care and Pediatricians, as well as Psychologists, Nurses, Social Workers, Counselors and other Mental Health Care Professionals.

CONTINUING EDUCATION

PHYSICIANS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Psychiatric Association (APA) and the Ohio Psychiatric Physicians Association (OPPA). The APA is accredited by the ACCME to provide continuing medical education for physicians.

- The American Psychiatric Association designates this live activity, ***Putting the Unique Needs of our Patient’s First: Compassion, Controversies & Crucial Conversations*** for a maximum of 9 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EVALUATION

This educational activity will be evaluated utilizing an online evaluation form to evaluate the effectiveness of the CME activity in meeting the identified educational needs and stated learning objectives in terms of satisfaction, knowledge, skills and any perceived commercial bias. At the conclusion of this educational event, you will be provided with a link to the evaluation form. After completing the evaluation you will be provided with an opportunity to print a certificate for continuing education credit.


PLANNING COMMITTEE DISCLOSURE

It is the policy of the APA to comply with the ACCME Standards for Commercial Support of CME. Planning committee members and related staff disclosures are on file and disclosed on program materials. Faculty participating in sponsored or jointly provided meetings of the APA are required to disclose to program participants any financial relationships with commercial interests that they (or their spouse/partner) have related to the content of their presentations. Faculty disclosures are identified as a faculty cover sheet with their respective syllabus/handout materials. Faculty are also responsible for disclosing any discussion of off-label or investigational use of a product.

The following individuals of the planning committee have indicated neither they, nor their spouse/partner, have any financial relationship with any commercial source: Karen Jacobs, DO, Cathleen Cerny, MD, Victoria Kelly, MD, Lindsay Poplinski, DO, Selena Magalotti, MD, Janet Shaw, MBA, Heather Theibert, DO, and Kristi Williams, MD.

SATURDAY, APRIL 22

TIME	
7 – 9 a.m.	Registration/Visit Exhibits
7:30 – 8:30 a.m.	Buffet Breakfast
7:30 – 8:30 a.m.	Medical Student Meeting/Breakfast
7:30 – 8:55 a.m.	OPPA Annual Business Meeting and Installation of Officers
8 – 4:30 p.m.	Poster Presentations
8:55 a.m.	Welcome and Opening Remarks - Cathleen Cerny, MD and Karen Jacobs, DO, 2023 Program Co-Chairs
9 – 10 a.m.	<p><i>Psychopharmacology Update</i></p> <p>Henry Nasrallah, MD, DLFAPA Professor of Psychiatry, Neurology and Neuroscience, University of Cincinnati College of Medicine</p> <p>The psychopharmacological toolbox for major psychiatric disorders is rapidly evolving. New mechanisms of action are being developed for the treatment of mood and psychotic disorders, which will expand the therapeutic armamentarium for psychiatric physicians. Most of the new drugs represent a genuine paradigm shift in psychopharmacology. In depression, the movement away from monoamines (serotonin and norepinephrine) is rapidly growing. The innovation began with the discovery of ketamine's rapid efficacy for treatment-resistant depression via the antagonism of the NMDA receptor. It is now extending to new agents that exert antidepressant effects through glutamatergic, and sigma 1 receptor agonism. Other drugs have antidepressant effect by agonist effects on the serotonin 5HT_{2A} receptor, which includes psilocybin and other psychedelics. Another discovery was the opioid pathways also mediate antidepressant effects. The treatment of postpartum depression focused on the GABA-A receptors, a completely different approach. In schizophrenia and the psychosis spectrum, 2 novel drugs are being actively developed and have had controlled trials that were successful. The first strategy is cholinergic agonist (Xanomeline) on the muscarinic M1 and M5 receptors, in combination with a peripheral anticholinergic drug (tropicium) to counteract the cholinergic side effects. There is a possibility of improving negative symptoms and cognitive deficits with this approach. The second innovation is the TAAR 1 trace amine pathway (Ulotaront), which has had a successful phase 2 trial and phase 3 is currently underway. Other mechanisms of action are also being explored for the treatment of psychosis. In summary, the field of psychopharmacology research is vibrant and will translate into novel interventions in psychiatric practice in the very near future.</p>
10 – 11 a.m.	<p><i>Pregnancy Termination: What Psychiatrists Need to Know</i></p> <p>Nina E. Ross, MD Assistant Professor of Psychiatry, Case Western Reserve University</p> <p>This presentation will review the information about pregnancy termination that psychiatrists need to know. Any psychiatrist who treats women from the age of menstruation to menopause must recognize that their patients could become pregnant and apply this knowledge into psychiatric treatment plans. Accordingly, psychiatrists who treat these women must also understand the landscape of pregnancy termination in the United States because this will inevitably affect women of reproductive age. We will review the literature on the relationship between pregnancy termination and mental health, including evaluating the problematic designs of many past studies and discussing the most up-to-date literature. We will review key elements of the past, present, and future of pregnancy termination legislation in the United States, including the recent U.S. Supreme Court Case Dobbs v. Jackson and its implications for both patients and psychiatrists.</p>
11 – 11:30 a.m.	Break and Visit Exhibits
11:30 a.m. – 12:30 p.m.	<p><i>Social Determinants of Health, Health Disparities, and Equity: A Wicked Problem?</i></p> <p>Faye Gary, EdD, RN, FAAN Case Western Reserve University</p> <p>The presentation will address the social context of health care, including a historical and contemporary perspective, about policies and practices that have helped to create and maintain health disparities. The presentation will conclude with a discussion about wicked problems embedded in health systems.</p>
12:30 – 1:30 p.m.	Buffet Lunch
1:30 – 2:30 p.m.	<p><i>Flash Talks</i></p> <p>New this year, is the integration of five-minute Flash Talk presentations by resident/fellow members, from multiple training programs throughout Ohio, who will share novel research to improve quality of care in psychiatric treatment. Flash Talks are designed to quickly engage participants by sharing an idea, methodologies and outcomes in a clear and concise manner.</p>



SATURDAY, APRIL 22

TIME	
2:30 – 3:30 p.m.	<p><i>Updates on Pharmacotherapy for Late Life Psychiatric Disorders</i></p> <p>Rajesh Tampi, MD Professor and Chairman, Department of Psychiatry, Inaugural Bhatia Family Endowed Chair in Psychiatry, Creighton University School of Medicine and Catholic Health Initiatives (CHI) Health Behavioral Health Services, Omaha, Nebraska.</p> <p>Psychiatric disorders are not uncommon among older adults. Approximately 200/o of older individuals in the United States present with a diagnosable psychiatric disorders. Common psychiatric disorders included anxiety disorders and depressive disorders. Substance use disorders, psychotic disorders and neurocognitive disorders are also seen fairly commonly among older adults. Aging is associated with various pharmacokinetic and pharmacodynamic changes in the human body. Available evidence indicates that older adults respond to treatment with psychotropic medications as well as younger individuals, but they tend to experience more side-effects form these medications. In this presentation, I will describe the pharmacokinetic and pharmacodynamic changes associated with aging. Additionally, I will then discuss the benefits and risk of using psychopharmacological agents among older adults. Furthermore, I will enumerate evidence based guidelines for the treatment of some common psychiatric disorders among older adults.</p> <div><p><i>This presentation is funded, in part, by the generosity of the The Henry and Amelia Nasrallah Lecture for Advances in Psychiatry</i></p></div>
3:30 – 3:45 p.m.	Break and Visit Exhibits
3:45 – 4:45 p.m.	<p><i>Evidence-Based Diagnosis and Treatment for Complex Trauma in Children and Adolescents</i></p> <p>Alissa Huth-Bocks, PhD Director of the Merrill Palmer Skillman Institute, Wayne State University</p> <p>Children and adolescents experience potentially traumatic events at high rates. The most common forms of trauma tend to be interpersonal in nature, and most occur within close relationships. Youth who experience multiple and prolonged interpersonal trauma are at greatest risk for mental health difficulties and pervasive developmental disruptions; this is sometimes referred to as 'complex trauma' or 'developmental trauma'. Accurate assessment and diagnosis of trauma-related disorders is critical, as trauma symptoms or reactions may mimic symptoms consistent with other psychiatric diagnoses leading to misdiagnosis and ineffective treatment. This presentation will present information on the prevalence of multiple types of traumatic events, evidence-based assessments for trauma exposures and traumatic stress reactions, challenging differential diagnoses, and core components of effective psychotherapeutic trauma treatments.</p>

SATURDAY, APRIL 22 - Evening

TIME	FUNCTION
	<p><i>Ohio Psychiatric Physicians Foundation Gala and Silent Auction</i> (more details coming soon)</p> <p>(schedule and activities subject to change slightly)</p>
5 – 8 p.m.	Cash Bar, Hors d'oeuvres, Silent Auction & FUN draising Activities
5:30 – 6 p.m.	OPPF Annual Awards Presentation (Ballroom)
6 – 8 p.m.	Announce FUN draising Activities Winners (Ballroom)



SUNDAY, APRIL 23

TIME	FUNCTION
8 – 8:55 a.m.	Visit Exhibits/Buffer Breakfast
8:40 – 8:55 a.m.	Poster Presentation Winners Announced (8:40-8:55)
9 – 10 a.m.	<p><i>Harm Reduction in Addiction Treatment</i></p> <p>Yarelis Estrada, MSPH Alliance for Collaborative Drug Checking, Urban Survivors Union, New York City Psychedelic Society</p> <p>Every overdose death is a policy failure. In the one year period ending in April of 2021, we lost over 100,000 lives to drug overdose deaths in our nation. There are many factors that got us where we are today, including the failed, racist war on drugs and resulting draconian drug policies and criminalization of people who use drugs, drug prohibition, the pervasive stigma of drug use and people who use drugs within our society and more specifically within the healthcare system and forced “tough love” and inflexible abstinence-based ideologies. Harm reduction provides an approach and practices that are rooted in nonjudgemental, person-centered care that meets each individual where they are and provides vital resources that are needed to keep people alive with dignity at that time. In this presentation I will provide different examples of harm reduction tools and practices and offer ideas that might help us collectively shift towards systemic changes that will not only save lives but foster community care in the process.</p>
10 – 10:30 a.m.	Break and Visit Exhibits
10:30 – 11:30 a.m.	<p><i>Mental Health Care for Transgender and Gender Diverse People</i></p> <p>Alex Keuroghlian, MD, MPH Director of Education and Training Programs, The Fenway Institute</p> <p>This session will contextualize mental health inequities across diagnostic categories within a gender minority stress framework, propose culturally responsive tailoring of evidence-based clinical practices, and offer strategies for building inclusive, affirming, and trauma-informed mental health care environments in order to optimize mental health outcomes for transgender and gender diverse people.</p>
11:30 a.m. – 12:30 p.m.	<p><i>What Exactly is Depression?</i></p> <p>Eric Messamore, MD, PhD Associate Professor of Psychiatry, Northeast Medical University</p> <p>Questions like “why am I so sad all the time?” or “how can this medication help?” arise because the brain requires explanations as intensely as the body demands oxygen. Framing depression as a “chemical imbalance” satisfies this need for explanation. It makes depression feel more understandable and less stigmatizing. And it explains how medications can help. This explanation, however, has been strongly criticized. Critics assert that there is no persuasive evidence of a chemical imbalance relevant to human depression (e.g., Moncrieff et al., 2022). These criticisms often attract significant media attention and controversy. Although the critical viewpoint has its own set of flaws, depression care based on now-conventional paradigms is often far from adequate. I will argue in this talk that the chemical imbalance explanation is like cotton candy. It is less substantial than it first appears, and harmful if overused. I will describe the syndromes of depressive illness in ways that will be consistent with scientific knowledge and clinical experience, and hopefully more useful for clinicians, patients, and society.</p>



Speakers



Yarelix Estrada, MSPH, is a first-generation Central American, drug policy and harm reduction researcher, advocate, and community outreach worker. Yarelix works as a City Research Scientist with the New York City Department of Health and Mental Hygiene conducting community-based harm reduction outreach and research. Her work is currently largely focused on implementation of the first higher-technology drug checking research study in New York City with local syringe service programs and an overdose prevention center. Yarelix is passionate about supporting people throughout the full continuum of drug use, from use for pleasure and healing to overdose prevention. She received her Master of Science in Public Health in Health Policy at the Johns Hopkins Bloomberg School of Public Health.



At Case Western Reserve University, Cleveland, Ohio, **Faye Gary, EdD, RN, FAAN**, is a Distinguished University Professor and the Medical Mutual of Ohio Kent W. Clapp Chair and Professor of Nursing. She holds a secondary appointment in the Department of Psychiatry, School of Medicine, and served on the National Advisory Council of the National Institutes of Health. Her work spans six continents. Dr. Gary is the Founding Director of the Provost Scholars Program. She has published more than 150 research/scholarly papers and has received numerous awards. Her latest (2022) textbook, *Population Health, and Health Disparities* is an interdisciplinary publication.



Alissa Huth-Bocks, PhD, is Director of the Merrill Palmer Skillman Institute for Child & Family Development and Professor of Psychology at Wayne State University in Detroit, Michigan. She is a licensed clinical psychologist with expertise in early childhood mental health. Through interdisciplinary and collaborative team science, her research has focused on understanding the effects of adversity, such as interpersonal violence, parental mental health and substance use disorders, and poverty, on family relationships and childhood development. Her translational research has focused on evaluating primary prevention and early intervention models to mitigate the effects of trauma on young children within healthcare and community settings.



Alex Keuroghlian, MD, MPH, is Associate Professor of Psychiatry, Harvard Medical School (HMS); Director, Division of Education and Training at The Fenway Institute; and Director and Michele and Howard J Kessler Chair, Division of Public and Community Psychiatry at Massachusetts General Hospital (MGH). He is principal investigator of the National LGBTQIA+ Health Education Center at The Fenway Institute, a HRSA BPHC-funded cooperative agreement to improve care for LGBTQIA+ people across the U.S., as well as the HRSA HAB-funded 2iS Coordinating Center for Technical Assistance, which implements interventions nationally for people with HIV. Dr. Keuroghlian established the MGH Psychiatry Gender Identity Program and is clerkship director for two senior electives in sexual and gender minority health at HMS. He also co-directs the HMS Sexual and Gender Minority Health Equity Initiative, which leads longitudinal medical curriculum and faculty development in LGBTQIA+ health.



When your new colleagues find out that you're a psychiatrist who also has a PhD in pharmacology... people start asking you questions about their most challenging cases. **Erik Messamore, MD, PhD** has been answering these types of questions for most of his clinical career. He holds a PhD in pharmacology, and had conducted Alzheimer drug development and schizophrenia biomarker research. He's been an ECT practitioner for over a decade and remains a complex case consultant in the areas of mood disorders and psychosis. He is an associate professor of psychiatry at Northeast Ohio Medical University and hosts a free weekly consultation and telementoring service for Ohio clinicians.



Speakers



Henry A. Nasrallah, MD, DFAPA is a widely recognized neuropsychiatrist, educator and researcher. Following his psychiatric residency at the University of Rochester and neuroscience fellowship at the NIH, he served for 18 years as chair of psychiatry at two universities (Ohio State and St. Louis) and as associate dean for four years at the University of Cincinnati College of Medicine. He is currently Vice-Chair for Faculty Development and Mentorship, Professor of Psychiatry, Neurology and Neuroscience, Medical Director of Neuropsychiatry Program and Director of the Schizophrenia Program in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine. Dr. Nasrallah's research focuses on the neurobiology and psychopharmacology of schizophrenia and psychotic mood disorders. He has published 440 scientific articles, 600 abstracts, 185 editorials, and 13 books. He is Editor-In-Chief of three journals (*Schizophrenia Research*, *Biomarkers in Neuropsychiatry* and *Current Psychiatry*) and is the co-founder of the Schizophrenia International Research Society (SIRS). He is a Fellow of the American College of Neuropsychopharmacology, Distinguished Fellow of the American Psychiatric Association and served as president of the Ohio Psychiatric Physicians Foundation, president of the American Academy of Clinical Psychiatrists, president of the Missouri Psychiatric Association and the Scientific Director of the CURESZ Foundation. He has twice received the NAMI Exemplary Psychiatrist Award and was chosen as the U.S.A. Teacher of the Year by the Psychiatric Times. He has received the Golden Apple Teaching Award at four different universities. He has received over 95 research grants and is listed annually in the book "Best Doctors in America".



Nina Ross, MD, completed her psychiatry residency at the University of Pittsburgh Medical Center Western Psychiatric Hospital, where she also completed the Academic Administrator Clinician Educator Track and the Women's Mental Health Area of Concentration. She attended forensic psychiatry fellowship at Case Western Reserve University, where she currently practices as a forensic and reproductive psychiatrist. Dr. Ross has published and presented locally and nationally on reproductive and forensic psychiatry topics. Dr. Ross currently serves as the co-chair of the American Academy of Psychiatry and the Law Gender Issues Committee.



Raj Tampi, MD is the Professor and Chairman, Department of Psychiatry, Inaugural Bhatia Family Endowed Chair in Psychiatry, Creighton University School of Medicine and Catholic Health Initiatives (CHI) Health Behavioral Health Services, Omaha, Nebraska. He is also an Adjunct Professor of Psychiatry at Yale School of Medicine, New Haven, Connecticut. Dr. Tampi is the Past President of the American Association for Geriatric Psychiatry (AAGP). He is also the inaugural Historian of the AAGP. Dr. Tampi is a Past President of the International Medical Graduates (IMG) Caucus at the American Psychiatric Association (APA). He is a Distinguished Fellow of the APA and of the AAGP.



Registration



Register online:
www.oppa.org



Ohio Psychiatric Physicians Association
PO Box 400
Dublin, OH 43017



(614) 763-0040



(614) 481-7559

1 Contact Information

Please print

Name _____
Degree ____ MD ____ DO ____ PhD ____ APN ____ LISW ____ LPCC
____ Other (please specify) _____
E-mail _____

Address _____

City/State/Zip _____
Phone _____ Fax _____

2 Registration Information

MEMBERS

Registration Type	Early Bird Rate By Mar. 10	Regular Rate	Late Rate After Apr. 10
Annual Psychiatric Update (April 22-23, 2023)			
OPPA Member	<input type="checkbox"/> \$225	<input type="checkbox"/> \$275	<input type="checkbox"/> \$325
OPPA Resident-Fellow Member	<input type="checkbox"/> \$150	<input type="checkbox"/> \$175	<input type="checkbox"/> \$200
Sat. Evening Gala/Silent Auction			
Per person	<input type="checkbox"/> \$75		

Registration Total \$ _____

NON-MEMBERS

Registration Type	Early Bird Rate By Mar. 10	Regular Rate	Late Rate After Apr. 10
Annual Psychiatric Update (April 22-23, 2023)			
Non-Member Psychiatrist, other Physician, APRN, or Psychologist	<input type="checkbox"/> \$375	<input type="checkbox"/> \$400	<input type="checkbox"/> \$450
Non-Member Resident-Fellow	<input type="checkbox"/> \$225	<input type="checkbox"/> \$250	<input type="checkbox"/> \$275
Counselor, Social Worker or Physician Assistant	<input type="checkbox"/> \$250	<input type="checkbox"/> \$300	<input type="checkbox"/> \$350
Sat. Evening Gala/Silent Auction			
Per person	<input type="checkbox"/> \$75		

Registration Total \$ _____

3 Payment Information

Registration Total \$ _____
(from the left)

Additional Options

- ☐ I would like to sponsor AND mentor a Medical Student to attend the OPPA Annual Psychiatric Update, April 22-23, 2023 \$125
- ☐ I am unable to serve as a mentor during the meeting but would like to sponsor a Medical Student to attend the OPPA Annual Psychiatric Update, April 22-23, 2023 \$125
- ☐ I am unable to sponsor a student at this time but would like to serve as a mentor at the OPPA Annual Psychiatric Update, April 22-23, 2023

**To make this a tax deductible contribution see details below*

Student Name _____

Email _____

If you do not have the name of a specific medical student, we will be happy to match you with a student who has expressed interest in attending if a sponsorship is available.

- ☐ I am a non-member psychiatrist and want to receive \$150 off my OPPA dues when I join the OPPA/APA by April 30, 2023.

Grand Total \$ _____

Method of Payment:

- ☐ Check payable to OPPA (registration fees)
☐ Check payable to OPPF (student sponsorship)

If you wish to pay by credit card please [register online](http://www.oppa.org)

** Tickets to the Saturday evening Gala are sold separate. For more details on the Saturday night event see page 8 or visit www.oppa.org.

* In order to make this a tax-deductible contribution, the registration and the sponsorship must be processed in two separate transactions. If paying by check, please mail two checks. Please make the sponsorship check payable to Ohio Psychiatric Physicians Foundation (OPPF) and your event registration check payable to OPPA. If you are paying by credit card, you will see two transactions on your statement.